Charles River first CRO to join forces with U.K. R&D matchmaking service

Increasingly acquisitive Charles River Laboratories ($CRL) has signed a new pact with the Milner Therapeutics Institute and Consortium (MTIC) that will see it become the first CRO to gain deeper ties with U.K. life science research centers through this consortium.

Wilmington, MA-based Charles River Laboratories will dig into MTIC’s ties with academic scientists and institutions in its life science R&D hub in Cambridge, U.K. This service reaches out to the pharma industry to help them develop new meds.

The consortium, which went live just last year, is currently made up of Astex, AstraZeneca ($AZN), GlaxoSmithKline ($GSK), and Shionogi, along with three academic centers: the University of Cambridge, the Babraham Institute, and the Sanger Institute.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Our partnership with the Milner Therapeutics Institute and Consortium further enables the collaboration between academics and pharmaceutical companies as they partner to investigate the therapeutic potential of their research,” said Emily Hickey, corporate SVP, global discovery services at Charles River.

“Charles River has had great success partnering with academic consortia in the United States, and we look forward to the same success in our first major research collaboration in the United Kingdom.”

Under the terms of the deal, financial details of which have not been shared, the academic organizations in the Consortium will be able to get in on Charles River’s early discovery and drug development resources and services.

This, Charles River said in a statement, will help them to speed up their early-stage drug development processes.

“We are excited to welcome Charles River as the newest partner to the Milner Therapeutics Institute,” said Tony Kouzarides, founder and director of the Milner Therapeutics Institute and Consortium.

“Charles River is uniquely positioned to help guide novel therapies from early discovery through safety testing. Their scientific expertise and wealth of industry knowledge will provide significant collaborative opportunities for the scientists in our program.”

Charles River has been ramping up the deals of late, recently paying out $585 million for WIL Research, and in June buying out CRO Blue Stream Laboratories, making it the CRO’s sixth deal in two years.

- check out the release

Related Articles:
Flow of deals keeps coming from Charles River with Blue Stream Labs buy
Charles River signs up to help Moderna with mRNA pipeline

Read more on

Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.